{
    "clinical_study": {
        "@rank": "142826", 
        "arm_group": [
            {
                "arm_group_label": "Travoprost/Timolol therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy"
            }, 
            {
                "arm_group_label": "Latanoprost/Timolol therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. 24-hour pressure monitoring will be carried out for this drug after 3 months of chronic dosing. All patients will be crossed over to therapy for 3 months with latanoprost/timolol fixed combination drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this crossover trial is to compare the 3-month, mean 24-hour\n      intraocular pressure (IOP) control and safety obtained with two popular fixed combinations\n      in glaucoma patients insufficiently controlled with latanoprost monotherapy.  This study\n      will compare the 24-hour efficacy of travoprost/timolol fixed combination without\n      benzalkonium chloride given once in the evening, versus the latanoprost/timolol fixed\n      combination given in the evening. It is assumed that travoprost/timolol fixed combination\n      will provide better quality of 24-hour pressure control."
        }, 
        "brief_title": "Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Glaucoma", 
        "condition_browse": {
            "mesh_term": "Glaucoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary open-angle glaucoma or exfoliative glaucoma\n\n          -  Patients who require additional IOP lowering on latanoprost monotherapy\n\n          -  Morning IOP greater than 20 mm Hg on latanoprost monotherapy\n\n          -  Untreated morning IOP greater than 26 mm Hg\n\n          -  Patients older than 29 years\n\n          -  Patients with early to moderate glaucoma (less than 14 decibel (dB) mean deviation\n             visual field loss attributed to glaucoma and 0.8 or better vertical cup-to-disc\n             ratio)\n\n          -  On therapy with latanoprost monotherapy for at least 3 months\n\n          -  Patients with a reliable visual field\n\n          -  Best corrected distance Snellen visual acuity >1/10\n\n          -  Corneal pachymetry within the 550 \u00b1 50 \u03bcm range\n\n          -  Patients should understand the study instructions\n\n          -  Patients willing to attend all follow-up appointments and willing to comply with\n             study medication usage\n\n          -  Patients who have open, normal appearing angles\n\n        Exclusion Criteria:\n\n          -  History of combined topical therapy\n\n          -  Contraindication to prostaglandins or timolol\n\n          -  History of ocular trauma or inflammation; intraocular surgery; severe dry eyes; use\n             of contact lenses\n\n          -  Sign of ocular infection except for mild blepharitis\n\n          -  Any corneal abnormality that could have affected the measurement of IOP\n\n          -  Chronic use of topical corticosteroids in the last 3 months before entering the study\n\n          -  Current, or previous use of systemic corticosteroid treatment\n\n          -  Uncontrolled systemic disease\n\n          -  Change of a systemic medication during the study period\n\n          -  Women of childbearing potential or lactating mothers\n\n          -  Inability to understand the instructions and adhere to medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "29 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779284", 
            "org_study_id": "A23"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Travoprost/Timolol therapy", 
                    "Latanoprost/Timolol therapy"
                ], 
                "description": "Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing", 
                "intervention_name": "Travoprost/timolol therapy", 
                "intervention_type": "Drug", 
                "other_name": "DuoTrav BAK Free"
            }, 
            {
                "arm_group_label": [
                    "Travoprost/Timolol therapy", 
                    "Latanoprost/Timolol therapy"
                ], 
                "description": "Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy", 
                "intervention_name": "Latanoprost/Timolol therapy", 
                "intervention_type": "Drug", 
                "other_name": "Xalacom"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Benzalkonium Compounds", 
                "Timolol", 
                "Latanoprost", 
                "Travoprost"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "glaucoma", 
            "fixed combinations", 
            "24-hour monitoring"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Thessaloniki", 
                    "country": "Greece", 
                    "zip": "546 36"
                }, 
                "name": "Glaucoma Unit, 1st University Department of Ophthalmology"
            }
        }, 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "2", 
        "official_title": "24-Hour Efficacy of Travoprost/Timolol Benzalkonium Chloride BAK Free Compared With Latanoprost/Timolol Fixed Combination Therapy in Subjects With Open-Angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Greece: National Organization of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluation of 24-hour pressure every 4 hours at habitual position with calibrated Goldmann technology tonometer", 
            "measure": "Mean 24-hour intraocular pressure reduction between the two medications", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779284"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Aristotle University Of Thessaloniki", 
            "investigator_full_name": "AGP Konstas", 
            "investigator_title": "Professor in Ophthalmology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "At each visit local and systemic adverse effects that occurred during the treatment period will be recorded.  Adverse events are evaluated by asking patients a general query about their state of health.", 
                "measure": "rate of adverse events with the two medications", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Selected indicators (break up time of tears, Schirmer test and degree of corneal stain after application of fluorescein) will be employed after 3 months of therapy to determine the health status of ocular surface with the two medications.", 
                "measure": "ocular surface indicators after 3 months of therapy with the two medications", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Aristotle University Of Thessaloniki", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aristotle University Of Thessaloniki", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}